Drugs / RM-718
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06239116 | Mar 2024 → Nov 2027 expected | Prader-Willi syndrome, acquired hypothalamic obesity | Rhythm Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-04 | Rhythm Pharmaceuticals, Inc. | Results Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity rhythmtx.com ↗ |
| 2024-01-04 | Rhythm Pharmaceuticals, Inc. | Regulatory Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates rhythmtx.com ↗
IND application for RM-718 accepted by the FDA |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-04 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity rhythmtx.com ↗ |
| 2024-03-25 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist rhythmtx.com ↗ |
| 2024-01-04 | Rhythm Pharmaceuticals, Inc. | Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates rhythmtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RM-718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239116 ↗ |
| Route | Subcutaneous | “Study drug (RM-718 or placebo) doses are administered weekly via subcutaneous injection.” NCT06239116 ↗ |